Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL

Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL

OBJECTIVE: Cancer detection has been reported in up to 27% of patients when lowering the PSA cutoff to 2.5 ng/mL. Although this practice could increase the number of biopsies performed, it also could lead to more frequent detection of significant prostate cancers at an organ-confined stage and/or a...

Full description

Bibliographic Details
Main Authors:	Katia R. Leite, Miguel Srougi, Marcos F. Dall'Oglio, Adriana Sanudo, Luiz H. Camara-Lopes
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia 2008-06-01
Series:	International Brazilian Journal of Urology
Subjects:	PSA prostate cancer biopsy diagnosis Gleason score tumor volume
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000300005

Similar Items

Comparison of Pathology and Prevalence of Prostate Cancer in Patients with PSA between 4-10 ng/ml
by: A Tabibi, et al.
Published: (2008-01-01)

PSA levels of 4.0 - 10 ng/ml and negative digital rectal examination: antibiotic therapy versus immediate prostate biopsy
by: Avraham Shtricker, et al.
Published: (2009-10-01)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
by: Tsung-Hsin Chang, et al.
Published: (2020-10-01)

A study of biological determinants of serum prostate specific antigen level in prostatic adenocarcinoma with normal, borderline, and high serum PSA levels
by: Anu Sumi Issac, et al.
Published: (2014-01-01)

Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens
by: Nelson Gianni de Lima, et al.
Published: (2013-06-01)

The effect on the sensitivities of PSA and PSA-age volume score of IPSS and nocturia in predicting positive prostate biopsy findings
by: O. Üçer, et al.
Published: (2017-06-01)

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
by: Gokhan Koc, MD, et al.
Published: (2017-01-01)

Determining the degree of alignment of prostate carcinoma in a rectal biopsy with radical prostatectomy in patients with prostate carcinoma
by: Kamaleddin Hassanzadeh, et al.
Published: (2021-02-01)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
by: Michael H. Johnson, et al.
Published: (2015-09-01)

Correlation between serum PSA, gleason score and histopathological grading of adenocarcinoma of prostate in patients undergoing TRUS guided prostatic biopsy in a tertiary care centre of Southern India
by: Veda Murthy Reddy Pogula, Karthikesh Omkaram, Ershad Hussain Galeti, Bhargava Reddy Kanchi V
Published: (2021-12-01)

Clinical and histopathological characteristics of prostate cancer in Erbil city/ Iraq
by: Narin Shakir Mola ahmed, et al.
Published: (2024-12-01)

Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: Our experience and review of the literature
by: Selcuk Sarıkaya, et al.
Published: (2014-12-01)

Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy
by: Katia Ramos Moreira Leite, et al.
Published: (2008-01-01)

Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer
by: Gelareh Vahabzadeh, et al.
Published: (2025-01-01)

CORRELATION BETWEEN SERUM TESTOSTERONE, BIOCHEMICAL AND CLINICAL MARKERS IN PROSTATE CANCER PATIENTS
by: Bogdan Roussev, et al.
Published: (2016-09-01)

High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy
by: Jonathan W. Lischalk, et al.
Published: (2024-03-01)

Correlação entre a graduação histológica de biópsias e do espécimen cirúrgico em câncer da prostata
by: José Cury, et al.

Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml−1 to 10 ng ml−1
by: Chi-Chen Zhang, et al.
Published: (2023-01-01)

Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
by: Solmaz Ohadian Moghadam, et al.
Published: (2025-01-01)

A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
by: Yasuhide Miyoshi, et al.
Published: (2022-11-01)

High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review
by: Jude O Okoye
Published: (2020-07-01)

A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer
by: Gelareh Vahabzadeh, et al.
Published: (2023-05-01)

Clinical-morphological characteristics of pathological changes in the prostate
by: Ilić Aleksandra, et al.
Published: (2019-01-01)

by: Betina Katz, et al.
Published: (2012-12-01)

The accuracy of pathological data for the prediction of insignificant prostate cancer
by: Betina Katz, et al.
Published: (2012-12-01)

Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy
by: Marcel Figueras, et al.
Published: (2024-10-01)

Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
by: Yiji Peng, et al.
Published: (2025-03-01)

Résultats de la biopsie prostatique chez les patients algériens avec un PSA élevé et/ou un toucher rectal suspect
by: M. Benatta, et al.
Published: (2012-09-01)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
by: Alexandros Fiamegos, et al.

Integration of PSAd and multiparametric MRI to forecast biopsy outcomes in biopsy-naïve patients with PSA 4~20 ng/ml
by: Lei Ren, et al.
Published: (2024-07-01)

Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy
by: Vincenzo Fiorentino, et al.
Published: (2020-12-01)

Correlation between Gleason Scores of Prostatic Biopsies and Radical Prostatectomy Specimens
by: Panitta Sitthinamsuwan, et al.
Published: (2009-01-01)

Relation between Serum Level of Total PSA and Free PSA/Total PSA Ratio with Grade of Prostate Cancer
by: Mohammad Yazdani, et al.
Published: (2013-10-01)

A second opinion pathology review improves the diagnostic concordance between prostate cancer biopsy and radical prostatectomy specimens
by: Takanori Maehara, et al.
Published: (2021-01-01)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
by: Hugo A. Socrates Castro, et al.

Association between gleason score, psa level, PSAD and prostate volume, in a series of patients with prostate adenocarcinoma
by: Benedetti-Padrón Inés, et al.
Published: (2012-06-01)

Multiparametric MRI targeted prostate biopsy: When omit systematic biopsy?
by: Pietro Pepe, et al.
Published: (2024-11-01)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
by: W. F. S. Busato, et al.
Published: (2015-04-01)

Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy
by: Marcos F. Dall'oglio, et al.
Published: (2005-06-01)

Upgrading of gleason score on radical prostatectomy specimen compared to the pre-operative needle core biopsy: An Indian experience
by: Rishi Nayyar, et al.
Published: (2010-01-01)